KRAS Q61-Mutant NSCLC study shows Q61H and Q61L have distinct molecular profiles and better outcomes with immunotherapy KRAS Q61-Mutant NSCLC Shows Distinct Molecular Patterns and Better Outcomes With Immunotherapy-Based Regimens A new study published in Clinical Cancer Research provides one...
KRAS Q61-Mutant NSCLC Shows Distinct Molecular Patterns and Better Outcomes With Immunotherapy-Based Regimens A new study published in Clinical Cancer Research provides one of the largest molecular and clinical analyses of patients with KRAS Q61 mutant NSCLC, a rare and...
Abstract This study aimed to develop a novel KRAS-targeting scaffold for non-small cell lung cancer (NSCLC) treatment by synthesizing and evaluating a heteroaromatic thiosemicarbazone compound (Htc). We hypothesized that the unique structural features of thiosemicarbazones would enable effective binding to...
Abstract KRAS G12C-mutant non-small cell lung cancer (NSCLC) has transitioned from a therapeutically problematic disease to a precision-targetable cancer, anchored by the landmark approvals of sotorasib and adagrasib. Yet despite these advances, responses remain limited in duration and multiple mechanisms...
Science Advances (2026). DOI: 10.1126/sciadv.aeb0794"> Model of PCDH7 mAb7–mediated tumor inhibition. Credit: Science Advances (2026). DOI: 10.1126/sciadv.aeb0794 An experimental antibody treatment that binds to a protein known as PCDH7 shrank tumors in preclinical models of non-small cell lung cancer (NSCLC),...
Abstract Introduction:KRAS Q61 mutations represent a heterogeneous molecular subgroup and account for 1–7% of allKRAS mutations in non-small cell lung cancer (NSCLC). The prognostic value of this cohort and its response to different treatment regimens remain unclear. Methods: Between 2011...
